materials studio software biovia materials studio academic research version 8.0 Search Results


b1910500 nevanimibe medchemexpress llc  (MedChemExpress)
94
MedChemExpress b1910500 nevanimibe medchemexpress llc
B1910500 Nevanimibe Medchemexpress Llc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/materials+studio+software+biovia+materials+studio+academic+research+version+8%2E0/Nevanimibe/pm34520735-129-33-35
Average 94 stars, based on 1 article reviews
b1910500 nevanimibe medchemexpress llc - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
normal goat serum in tbst  (Thermo Fisher)
98
Thermo Fisher normal goat serum in tbst
Normal Goat Serum In Tbst, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/materials+studio+software+biovia+materials+studio+academic+research+version+8%2E0/Tween+20/10__1677_slash_joe___10___0297-66-6-43
Average 98 stars, based on 1 article reviews
normal goat serum in tbst - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
insulin  (ALPCO)
96
ALPCO insulin
Insulin, supplied by ALPCO, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/materials+studio+software+biovia+materials+studio+academic+research+version+8%2E0/Mouse+Insulin+ELISA/pm27496881-60-34-41
Average 96 stars, based on 1 article reviews
insulin - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
tween 20  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology tween 20
Tween 20, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/materials+studio+software+biovia+materials+studio+academic+research+version+8%2E0/Tween-20/pm21303947-105-7-31
Average 96 stars, based on 1 article reviews
tween 20 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
biovia discovery studio software  (Accelrys)
86
Accelrys biovia discovery studio software
Biovia Discovery Studio Software, supplied by Accelrys, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/materials+studio+software+biovia+materials+studio+academic+research+version+8%2E0/biovia+discovery+software+studio/pm41839925-256-13-13
Average 86 stars, based on 1 article reviews
biovia discovery studio software - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
rabbit polyclonal anti caspase 3 primary antibody  (Danaher Inc)
99
Danaher Inc rabbit polyclonal anti caspase 3 primary antibody
Rabbit Polyclonal Anti Caspase 3 Primary Antibody, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/materials+studio+software+biovia+materials+studio+academic+research+version+8%2E0/Rabbit+Polyclonal+Anti-JAK2+(phospho+Y1007)+antibody/pm17149372-89-4-9
Average 99 stars, based on 1 article reviews
rabbit polyclonal anti caspase 3 primary antibody - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
sch772984  (MedChemExpress)
98
MedChemExpress sch772984
A, Representative immunoblotting of PKC, ERK and AKT in Caco-2/bbe cells treated with different TKI drugs for 6 days (left), and quantification of the relative abundance of phosphorylated protein normalized to total protein from 3 independent experiments (right). B, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor (GDC-0994), PKC inhibitor (RO.31.8220), AKT inhibitor (MK-2206) or afatinib at indicated concentrations for 6 days. Similar results were found in 3 independent experiments. C, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor <t>(SCH772984)</t> for 6 days. Similar results were found in 3 independent experiments. D, mRNA expression of several ion transport proteins in Caco-2/bbe cells treated with AKT inhibitor (MK-2206) for 6 days. n = 3. E, mRNA expression of ion transport proteins in Caco-2/bbe cells treated with ERK inhibitor (SCH772984) for 6 days. F, initial Cl - HCO 3 - exchange rates are shown for Caco-2/bbe cells treated with indicated compounds for 6 days. The number of experiments used in quantification is indicated inside each bar. Data presented as mean ± s.e.m. *, p < 0.05, **, p < 0.01, **, p < 0.001, as compared to DMSO and non-ErbB TKI (A, Student’s t-test), as compared to DMSO (D, E, F, ANOVA followed by post hoc Tukey analysis).
Sch772984, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/materials+studio+software+biovia+materials+studio+academic+research+version+8%2E0/SCH772984/bio_rxiv__2020__10__16__342139-135-9-13
Average 98 stars, based on 1 article reviews
sch772984 - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
mgcl2  (Bio-Rad)
99
Bio-Rad mgcl2
A, Representative immunoblotting of PKC, ERK and AKT in Caco-2/bbe cells treated with different TKI drugs for 6 days (left), and quantification of the relative abundance of phosphorylated protein normalized to total protein from 3 independent experiments (right). B, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor (GDC-0994), PKC inhibitor (RO.31.8220), AKT inhibitor (MK-2206) or afatinib at indicated concentrations for 6 days. Similar results were found in 3 independent experiments. C, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor <t>(SCH772984)</t> for 6 days. Similar results were found in 3 independent experiments. D, mRNA expression of several ion transport proteins in Caco-2/bbe cells treated with AKT inhibitor (MK-2206) for 6 days. n = 3. E, mRNA expression of ion transport proteins in Caco-2/bbe cells treated with ERK inhibitor (SCH772984) for 6 days. F, initial Cl - HCO 3 - exchange rates are shown for Caco-2/bbe cells treated with indicated compounds for 6 days. The number of experiments used in quantification is indicated inside each bar. Data presented as mean ± s.e.m. *, p < 0.05, **, p < 0.01, **, p < 0.001, as compared to DMSO and non-ErbB TKI (A, Student’s t-test), as compared to DMSO (D, E, F, ANOVA followed by post hoc Tukey analysis).
Mgcl2, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/materials+studio+software+biovia+materials+studio+academic+research+version+8%2E0/MgCl2/pm37386215-413-14-42
Average 99 stars, based on 1 article reviews
mgcl2 - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
plasma insulin  (ALPCO)
98
ALPCO plasma insulin
A, Representative immunoblotting of PKC, ERK and AKT in Caco-2/bbe cells treated with different TKI drugs for 6 days (left), and quantification of the relative abundance of phosphorylated protein normalized to total protein from 3 independent experiments (right). B, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor (GDC-0994), PKC inhibitor (RO.31.8220), AKT inhibitor (MK-2206) or afatinib at indicated concentrations for 6 days. Similar results were found in 3 independent experiments. C, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor <t>(SCH772984)</t> for 6 days. Similar results were found in 3 independent experiments. D, mRNA expression of several ion transport proteins in Caco-2/bbe cells treated with AKT inhibitor (MK-2206) for 6 days. n = 3. E, mRNA expression of ion transport proteins in Caco-2/bbe cells treated with ERK inhibitor (SCH772984) for 6 days. F, initial Cl - HCO 3 - exchange rates are shown for Caco-2/bbe cells treated with indicated compounds for 6 days. The number of experiments used in quantification is indicated inside each bar. Data presented as mean ± s.e.m. *, p < 0.05, **, p < 0.01, **, p < 0.001, as compared to DMSO and non-ErbB TKI (A, Student’s t-test), as compared to DMSO (D, E, F, ANOVA followed by post hoc Tukey analysis).
Plasma Insulin, supplied by ALPCO, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/materials+studio+software+biovia+materials+studio+academic+research+version+8%2E0/Insulin+ELISA/10__4172_slash_2155___6156__s13___012-41-0-7
Average 98 stars, based on 1 article reviews
plasma insulin - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
mitoxantrone selleck chemicals s1889  (MedChemExpress)
95
MedChemExpress mitoxantrone selleck chemicals s1889
A, Representative immunoblotting of PKC, ERK and AKT in Caco-2/bbe cells treated with different TKI drugs for 6 days (left), and quantification of the relative abundance of phosphorylated protein normalized to total protein from 3 independent experiments (right). B, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor (GDC-0994), PKC inhibitor (RO.31.8220), AKT inhibitor (MK-2206) or afatinib at indicated concentrations for 6 days. Similar results were found in 3 independent experiments. C, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor <t>(SCH772984)</t> for 6 days. Similar results were found in 3 independent experiments. D, mRNA expression of several ion transport proteins in Caco-2/bbe cells treated with AKT inhibitor (MK-2206) for 6 days. n = 3. E, mRNA expression of ion transport proteins in Caco-2/bbe cells treated with ERK inhibitor (SCH772984) for 6 days. F, initial Cl - HCO 3 - exchange rates are shown for Caco-2/bbe cells treated with indicated compounds for 6 days. The number of experiments used in quantification is indicated inside each bar. Data presented as mean ± s.e.m. *, p < 0.05, **, p < 0.01, **, p < 0.001, as compared to DMSO and non-ErbB TKI (A, Student’s t-test), as compared to DMSO (D, E, F, ANOVA followed by post hoc Tukey analysis).
Mitoxantrone Selleck Chemicals S1889, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/materials+studio+software+biovia+materials+studio+academic+research+version+8%2E0/Mitoxantrone/pmc05928226__41467_2018_4010_MOESM1_ESM-228-57-64
Average 95 stars, based on 1 article reviews
mitoxantrone selleck chemicals s1889 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
biovis filter  (Biovis Diagnostik MVZ)
90
Biovis Diagnostik MVZ biovis filter
A, Representative immunoblotting of PKC, ERK and AKT in Caco-2/bbe cells treated with different TKI drugs for 6 days (left), and quantification of the relative abundance of phosphorylated protein normalized to total protein from 3 independent experiments (right). B, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor (GDC-0994), PKC inhibitor (RO.31.8220), AKT inhibitor (MK-2206) or afatinib at indicated concentrations for 6 days. Similar results were found in 3 independent experiments. C, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor <t>(SCH772984)</t> for 6 days. Similar results were found in 3 independent experiments. D, mRNA expression of several ion transport proteins in Caco-2/bbe cells treated with AKT inhibitor (MK-2206) for 6 days. n = 3. E, mRNA expression of ion transport proteins in Caco-2/bbe cells treated with ERK inhibitor (SCH772984) for 6 days. F, initial Cl - HCO 3 - exchange rates are shown for Caco-2/bbe cells treated with indicated compounds for 6 days. The number of experiments used in quantification is indicated inside each bar. Data presented as mean ± s.e.m. *, p < 0.05, **, p < 0.01, **, p < 0.001, as compared to DMSO and non-ErbB TKI (A, Student’s t-test), as compared to DMSO (D, E, F, ANOVA followed by post hoc Tukey analysis).
Biovis Filter, supplied by Biovis Diagnostik MVZ, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/materials+studio+software+biovia+materials+studio+academic+research+version+8%2E0/biovis+filter/10__1515_slash_jwld___2017___0066-85-44-44
Average 90 stars, based on 1 article reviews
biovis filter - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
ripa buffer  (Abcam)
99
Abcam ripa buffer
A, Representative immunoblotting of PKC, ERK and AKT in Caco-2/bbe cells treated with different TKI drugs for 6 days (left), and quantification of the relative abundance of phosphorylated protein normalized to total protein from 3 independent experiments (right). B, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor (GDC-0994), PKC inhibitor (RO.31.8220), AKT inhibitor (MK-2206) or afatinib at indicated concentrations for 6 days. Similar results were found in 3 independent experiments. C, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor <t>(SCH772984)</t> for 6 days. Similar results were found in 3 independent experiments. D, mRNA expression of several ion transport proteins in Caco-2/bbe cells treated with AKT inhibitor (MK-2206) for 6 days. n = 3. E, mRNA expression of ion transport proteins in Caco-2/bbe cells treated with ERK inhibitor (SCH772984) for 6 days. F, initial Cl - HCO 3 - exchange rates are shown for Caco-2/bbe cells treated with indicated compounds for 6 days. The number of experiments used in quantification is indicated inside each bar. Data presented as mean ± s.e.m. *, p < 0.05, **, p < 0.01, **, p < 0.001, as compared to DMSO and non-ErbB TKI (A, Student’s t-test), as compared to DMSO (D, E, F, ANOVA followed by post hoc Tukey analysis).
Ripa Buffer, supplied by Abcam, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/materials+studio+software+biovia+materials+studio+academic+research+version+8%2E0/RIPA+Buffer/pmc08222966-79-8-10
Average 99 stars, based on 1 article reviews
ripa buffer - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

Image Search Results


A, Representative immunoblotting of PKC, ERK and AKT in Caco-2/bbe cells treated with different TKI drugs for 6 days (left), and quantification of the relative abundance of phosphorylated protein normalized to total protein from 3 independent experiments (right). B, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor (GDC-0994), PKC inhibitor (RO.31.8220), AKT inhibitor (MK-2206) or afatinib at indicated concentrations for 6 days. Similar results were found in 3 independent experiments. C, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor (SCH772984) for 6 days. Similar results were found in 3 independent experiments. D, mRNA expression of several ion transport proteins in Caco-2/bbe cells treated with AKT inhibitor (MK-2206) for 6 days. n = 3. E, mRNA expression of ion transport proteins in Caco-2/bbe cells treated with ERK inhibitor (SCH772984) for 6 days. F, initial Cl - HCO 3 - exchange rates are shown for Caco-2/bbe cells treated with indicated compounds for 6 days. The number of experiments used in quantification is indicated inside each bar. Data presented as mean ± s.e.m. *, p < 0.05, **, p < 0.01, **, p < 0.001, as compared to DMSO and non-ErbB TKI (A, Student’s t-test), as compared to DMSO (D, E, F, ANOVA followed by post hoc Tukey analysis).

Journal: bioRxiv

Article Title: Chronic exposure of ErbB TKIs inhibits DRA expression and activity through an ERK/Elk-1/CREB/AP-1 dependent pathway

doi: 10.1101/2020.10.16.342139

Figure Lengend Snippet: A, Representative immunoblotting of PKC, ERK and AKT in Caco-2/bbe cells treated with different TKI drugs for 6 days (left), and quantification of the relative abundance of phosphorylated protein normalized to total protein from 3 independent experiments (right). B, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor (GDC-0994), PKC inhibitor (RO.31.8220), AKT inhibitor (MK-2206) or afatinib at indicated concentrations for 6 days. Similar results were found in 3 independent experiments. C, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor (SCH772984) for 6 days. Similar results were found in 3 independent experiments. D, mRNA expression of several ion transport proteins in Caco-2/bbe cells treated with AKT inhibitor (MK-2206) for 6 days. n = 3. E, mRNA expression of ion transport proteins in Caco-2/bbe cells treated with ERK inhibitor (SCH772984) for 6 days. F, initial Cl - HCO 3 - exchange rates are shown for Caco-2/bbe cells treated with indicated compounds for 6 days. The number of experiments used in quantification is indicated inside each bar. Data presented as mean ± s.e.m. *, p < 0.05, **, p < 0.01, **, p < 0.001, as compared to DMSO and non-ErbB TKI (A, Student’s t-test), as compared to DMSO (D, E, F, ANOVA followed by post hoc Tukey analysis).

Article Snippet: Reagents were from Cayman Chemical: nigericin (#11437), GDC-0994 (#21107), SCH772984 (#19166), RO.31.8220 (#13334); MedChemExpress: T-5224 (HY-12270); Biovision: MK-2206 (1888-500); APExBIO: neratinib (A8322), CFTR mh -172 (B1435); AK Scientific: lapatinib (A817); Sigma: afatinib (A170920), dasatinib (SML2589), gefitinib (SML1657), osimertinib (A1577172), Suntinib (PZ0012), imatinib (SML1027).

Techniques: Western Blot, Expressing

A, identification of TRE site for AP-1 (C-Fos/C-Jun) binding in human SLC26A3 and SLC26A6 genes. B, representative immunoblotting of pERK, total ERK, pCREB, total CREB, C-Jun and C-Fos in Caco-2/bbe cells treated with indicated TKIs for 6 days. Similar results were found in 3 independent experiments. Quantification was performed to calculate the ratio of phosphorylated to total protein (below left) and the relative abundance to β-actin (below right). C, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor (SCH772984) at indicated concentrations for 6 days. Similar results were found in 3 independent experiments .D, Representative immunoblotting of CFTR and DRA in Caco-2/bbe cells treated with AP-1 inhibitor T-5224 at indicated concentrations for 6 days. Similar results were found in 3 independent experiments. E, mRNA expression of CREB, C-Fos and C-Jun in Caco-2/bbe cells after treatment with indicated drugs for 6 days. n = 3. Data presented as mean ± s.e.m. *, p < 0.05, ***, p < 0.001, as compared to DMSO and non-ErbB TKI (A, Student’s t-test), as compared to DMSO (D, E) (ANOVA followed by post hoc Tukey analysis).

Journal: bioRxiv

Article Title: Chronic exposure of ErbB TKIs inhibits DRA expression and activity through an ERK/Elk-1/CREB/AP-1 dependent pathway

doi: 10.1101/2020.10.16.342139

Figure Lengend Snippet: A, identification of TRE site for AP-1 (C-Fos/C-Jun) binding in human SLC26A3 and SLC26A6 genes. B, representative immunoblotting of pERK, total ERK, pCREB, total CREB, C-Jun and C-Fos in Caco-2/bbe cells treated with indicated TKIs for 6 days. Similar results were found in 3 independent experiments. Quantification was performed to calculate the ratio of phosphorylated to total protein (below left) and the relative abundance to β-actin (below right). C, Representative immunoblotting of Caco-2/bbe cells treated with ERK inhibitor (SCH772984) at indicated concentrations for 6 days. Similar results were found in 3 independent experiments .D, Representative immunoblotting of CFTR and DRA in Caco-2/bbe cells treated with AP-1 inhibitor T-5224 at indicated concentrations for 6 days. Similar results were found in 3 independent experiments. E, mRNA expression of CREB, C-Fos and C-Jun in Caco-2/bbe cells after treatment with indicated drugs for 6 days. n = 3. Data presented as mean ± s.e.m. *, p < 0.05, ***, p < 0.001, as compared to DMSO and non-ErbB TKI (A, Student’s t-test), as compared to DMSO (D, E) (ANOVA followed by post hoc Tukey analysis).

Article Snippet: Reagents were from Cayman Chemical: nigericin (#11437), GDC-0994 (#21107), SCH772984 (#19166), RO.31.8220 (#13334); MedChemExpress: T-5224 (HY-12270); Biovision: MK-2206 (1888-500); APExBIO: neratinib (A8322), CFTR mh -172 (B1435); AK Scientific: lapatinib (A817); Sigma: afatinib (A170920), dasatinib (SML2589), gefitinib (SML1657), osimertinib (A1577172), Suntinib (PZ0012), imatinib (SML1027).

Techniques: Binding Assay, Western Blot, Expressing